Quoin Pharmaceuticals FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million

Reuters03-26

<a href="https://laohu8.com/S/QNRX">Quoin Pharmaceuticals</a> FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million

Quoin published a press release providing a corporate update and reporting fourth-quarter and full-year 2025 financial results.
Net loss widened to USD 4.3 million in Q4 2025, and to USD 15.8 million for FY 2025.
Research and development expense rose to USD 9.8 million for FY 2025, nearly tripling, while general and administrative expense increased to USD 6.5 million, up 9.5%.
Cash, cash equivalents and marketable securities totaled USD 18.7 million at year-end 2025, and Quoin said this is expected to fund operations into 2027.
Michael Myers said the company is preparing to initiate a Phase 3 study for QRX003 in Netherton syndrome in 2026 and is targeting an NDA filing in 2027, with topline data from two whole-body Netherton syndrome trials expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260830PRIMZONEFULLFEED9679083) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622570558?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 20:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622570558","market":"us","top_or_hot":-1,"title":"Quoin Pharmaceuticals FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/QNRX\">Quoin Pharmaceuticals</a> FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Quoin published a press release providing a corporate update and reporting fourth-quarter and full-year 2025 financial results.\n        </li>\n<li>\n          Net loss widened to USD 4.3 million in Q4 2025, and to USD 15.8 million for FY 2025.\n        </li>\n<li>\n          Research and development expense rose to USD 9.8 million for FY 2025, nearly tripling, while general and administrative expense increased to USD 6.5 million, up 9.5%.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities totaled USD 18.7 million at year-end 2025, and Quoin said this is expected to fund operations into 2027.\n        </li>\n<li>\n          Michael Myers said the company is preparing to initiate a Phase 3 study for QRX003 in Netherton syndrome in 2026 and is targeting an NDA filing in 2027, with topline data from two whole-body Netherton syndrome trials expected in the second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260830PRIMZONEFULLFEED9679083) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quoin Pharmaceuticals FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuoin Pharmaceuticals FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 20:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/QNRX\">Quoin Pharmaceuticals</a> FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Quoin published a press release providing a corporate update and reporting fourth-quarter and full-year 2025 financial results.\n        </li>\n<li>\n          Net loss widened to USD 4.3 million in Q4 2025, and to USD 15.8 million for FY 2025.\n        </li>\n<li>\n          Research and development expense rose to USD 9.8 million for FY 2025, nearly tripling, while general and administrative expense increased to USD 6.5 million, up 9.5%.\n        </li>\n<li>\n          Cash, cash equivalents and marketable securities totaled USD 18.7 million at year-end 2025, and Quoin said this is expected to fund operations into 2027.\n        </li>\n<li>\n          Michael Myers said the company is preparing to initiate a Phase 3 study for QRX003 in Netherton syndrome in 2026 and is targeting an NDA filing in 2027, with topline data from two whole-body Netherton syndrome trials expected in the second half of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260830PRIMZONEFULLFEED9679083) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BKPKM429.USD","symbol_name":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL64PZGH:1","article_id":"2622570558","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622570558","pubTimestamp":1774528291,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Quoin published a press release providing a corporate update and reporting fourth-quarter and full-year 2025 financial results.Net loss widened to USD 4.3 million in Q4 2025, and to USD 15.8 million for FY 2025.Research and development expense rose to USD 9.8 million for FY 2025, nearly tripling, while general and administrative expense increased to USD 6.5 million, up 9.5%.Cash, cash equivalents and marketable securities totaled USD 18.7 million at year-end 2025, and Quoin said this is expected to fund operations into 2027.Michael Myers said the company is preparing to initiate a Phase 3 study for QRX003 in Netherton syndrome in 2026 and is targeting an NDA filing in 2027, with topline data from two whole-body Netherton syndrome trials expected in the second half of 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","QNRX":"Quoin Pharmaceuticals","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4139":"生物科技","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","BK4112":"金融交易所和数据","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4588":"碎股","NDAQ":"纳斯达克OMX交易所"},"translate_title":"Quoin Pharmaceuticals 2025财年净亏损扩大76.34%至1580万美元；现金上涨14.85%至1,870万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"QNRX":0.9,"NDAQ":0.9},"content_text":"Quoin Pharmaceuticals FY2025 net loss widens 76.34% to $15.8 million; cash climbs 14.85% to $18.7 million\n    \n\n\n          Quoin published a press release providing a corporate update and reporting fourth-quarter and full-year 2025 financial results.\n        \n\n          Net loss widened to USD 4.3 million in Q4 2025, and to USD 15.8 million for FY 2025.\n        \n\n          Research and development expense rose to USD 9.8 million for FY 2025, nearly tripling, while general and administrative expense increased to USD 6.5 million, up 9.5%.\n        \n\n          Cash, cash equivalents and marketable securities totaled USD 18.7 million at year-end 2025, and Quoin said this is expected to fund operations into 2027.\n        \n\n          Michael Myers said the company is preparing to initiate a Phase 3 study for QRX003 in Netherton syndrome in 2026 and is targeting an NDA filing in 2027, with topline data from two whole-body Netherton syndrome trials expected in the second half of 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260830PRIMZONEFULLFEED9679083) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622570558","isCrawlerRequest":true}